Mepolizumab 相關新聞
Mepolizumab 目前有 0 則相關新聞報導,預測適應症 20 個。
本頁整合 Mepolizumab 的 AI 預測適應症與最新健康新聞,橘色標示的適應症表示近期有相關新聞報導。
藥物資訊
- 原適應症:Severe eosinophilic asthmaNucala is indicated as an add-on treatment for severe refractory eosinophilic asthma in adults, adolescents and children aged 6 years and older . Chronic rhinosinusitis with...
- 證據等級:L5
- 預測適應症(20 個):
- thrombocytopenia due to immune destruction(99.7%)
- primary release disorder of platelets(99.6%)
- pseudo-von Willebrand disease(99.4%)
- autoimmune thrombocytopenic(99.3%)
- Glanzmann thrombasthenia(99.3%)
- Evans syndrome(98.6%)
- neonatal thrombocytopenia(98.6%)
- autosomal thrombocytopenia with normal platelets(98.4%)
- filariasis(97.7%)
- mixed-type autoimmune hemolytic anemia(96.6%)
- drug-induced autoimmune hemolytic anemia(96.4%)
- cyclic hematopoiesis(96.3%)
- proteinuria(95.9%)
- syndromic constitutional thrombocytopenia(95.9%)
- neonatal autoimmune hemolytic anemia(95.8%)
- paroxysmal nocturnal hemoglobinuria(95.5%)
- fetal and neonatal alloimmune thrombocytopenia(95.3%)
- hemorrhagic disorder due to a constitutional thrombocytopenia(94.6%)
- bleeding diathesis due to a collagen receptor defect(94.4%)
- Scott syndrome(94.4%)
相關新聞(0 則)
目前沒有相關新聞報導。當有新聞提到此藥物時,系統會自動收集並顯示在這裡。
免責聲明:本頁新聞由系統自動收集,僅供研究參考,不構成醫療建議。